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Abstract (En) 
 
 
The current limit of knowledge advancement in proteomic analysis of gliomas, the most 
common primary malignant brain tumors, is related to the high sensitivity required to detect specific 
biomarkers within few cells volumes. To address this problem we developed a quantitative 
approach to eventually enable precise, high throughput and low cost analysis of glial cells with 
potential capability of real-time pathological screening and subtyping of brain tumors.  
A device consisting in micro-fabricated wells capable to isolate and host living astrocytes 
was designed and functionalized. Then for the fabrication of a nanobiosensor, able to detect in small 
volumes the presence of specific biomarkers, ideally for multiplexing assays and meant to fit within 
the small dimensions of this microdevice, an approach consisting in DNA-directed-immobilization 
(DDI) of biotinylated antibodies (Abs) on a single stranded DNA (ssDNA) nanoarray, produced by 
Atomic Force Microscopy (AFM) nanografting, was carefully optimized. The proof of concept was 
realized with Abs specific for Glial Fibrillary Acidic Protein (GFAP), a biomarker which belongs to 
the family of intermediate filaments and is crucial in cell’s differentiation, within a platform ready 
for parallelization. 
Nanosized patches of thiol modified ssDNA were prepared by AFM-based nanografting 
inside a matrix of self assembled monolayers (SAM) of alkanethiol-modified gold surfaces. 
Subsequently a complementary DNA strand (cDNA) conjugated to streptavidin (STV) was allowed 
to covalently bind to the patch by sequence specific DNA hybridization. Finally the biotin binding 
sites of STV were exploited to immobilize biotinylated monoclonal GFAP Abs (already in use for 
ELISA assays) on the top of those nanopatches. The efficiency of those nano-immuno arrays was 
tested by successfully obtaining the immobilization of purified recombinant GFAP protein, down to 
a concentration of 4 nM, firstly in standard PBS then in multicells’ lysate obtained from U87 glial 
cultures. The immobilization was detected by means of AFM measuring step by step the increases 
in the height of the patches and excluding modification of the roughness of both the SAM and the 
nanopatches after incubation with the cells’ lysate through a signal to noise ratio analysis. Titration 
curves for a comparison of sensitivity between this technique and the conventional ELISA assays 
are provided; they indeed confirm that the sensitivity of our nanosensors is at least that of ELISA, 
with the advantage of the scalability of the device. 
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Abstract (It) 
 
 
L’attuale limite di avanzamento dello stato dell’arte dell’analisi proteomica dei gliomi 
cerebrali, la classe istologica di tumori cerebrali più frequente ed aggressiva, è legato alla difficoltà 
di individuare specifici biomarkers in piccoli volumi cellulari.  Per superare questo limite si è deciso 
di sviluppare un approccio nanoquantitativo che consenta un’analisi proteomica precisa, ad alta 
sensibilità e basso costo, degli astrociti tumorali, con potenzialità di screening in tempo reale e 
sottotipizzazione di tumori cerebrali. Previa fabbricazione e funzionalizzazione di micro pozzetti 
idonei ad ospitare cellule astrocitarie, ci si è dedicati alla realizzazione di biosensori in grado di 
riconoscere specifici biomarkers e di essere accoppiati ai micro pozzetti. Al fine di immobilizzare 
anticorpi specifici per proteine di interesse in ambito neuroncologico, è stato scelto un approccio 
basato sul nanografting con Microscopio a Forza Atomica (AFM) e sull’immobilizzazione diretta 
sul DNA di anticorpi (DDI). In particolare la prova concettuale è stata condotta con anticorpi 
specifici per la Glial Fibrillary Acidic Protein (GFAP), un marcatore della differenziazione 
astrocitaria appartenente alla famiglia dei filamenti intermedi intracellulari, su una piattaforma atta 
ad una successiva parallelizzazione. 
I nanocostrutti responsabili del riconoscimento della proteina d’interesse, sono stati realizzati 
partendo da molecole di DNA a singola elica (ssDNA) graftate in una matrice di monostrati 
autoassemblati (SAM) di superfici d’oro alchiltiolo modificato. Al fine di sfruttare la capacità della 
streptavidina (STV) di legarsi ad anticorpi biotinilati è stata successivamente indotta l’ibridazione di 
un filamento di DNA complementare (cDNA) a quello precedentemente immobilizzato sulla 
superficie nanoassemblata che presentasse anche una coda di STV. I siti di legame per la biotina 
intrinseci al tetramero di STV sono quindi stati sfruttati per immobilizzare sulla superficie dei 
nanocostrutti degli anticorpi monoclonali biotinilati specifici per GFAP (già in uso per i protocolli 
ELISA). L’efficienza dei nano-immuno costrutti così ottenuti è stata testata ottenendo 
l’immobilizzazione di GFAP ricombinante anche a basse concentrazioni (fino a 4nM), sia in 
presenza di standard PBS, sia in presenza di un lisato multicellulare ottenuto da colture gliali di 
cellule U87. L’immobilizzazione di GFAP è stata confermata dall’incremento in altezza dei 
nanocostrutti misurato all’AFM escludendo modificazioni del rapporto segnale/rumore sia del SAM 
che dei nanocostrutti prima e dopo aggiunta di lisato multicellulare. Il limite di sensibilità del 
prototipo così ottenuto è stato confrontato con quello raggiungibile con protocolli standard ELISA, 
mostrando una sensibilità almeno comparabile all’ELISA a fronte di un maggiore potenziale 
diagnostico legato alla sua scalabilità. 
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1.1 Background 
 
Based upon the latest genetic and proteomic insights into cancer’ biology, which opened 
new avenues for novel applied clinical research, trends in oncology highlight that molecular 
characterization of the tumorigenesis process will be essential in tomorrow’s clinical practice to 
predict prognosis and guide therapy. Noteworthy, the promise of individualized molecular 
medicine, which is particularly relevant to oncology because even similarly classified tumors can 
follow quite different clinical outcomes, could be realized by identifying molecular targets for 
therapy and by measuring tangible response or regression in clinical trials. 
 Specific patterns of protein expression in tumors and matched normal tissues can now be 
reliably analyzed using quantitative proteomic techniques. Among them the most effective are 
enzyme-linked immunosorbent assay (ELISA), two-dimensional gel electrophoresis (2DGE) and 
matrix-assisted laser desorption ionization time of flight (MALDI-TOF) mass spectrometry, which 
allow to simultaneously identify and characterize differentially expressed proteins. Nevertheless, 
arrays of proteins with well-defined feature size and spacing already demonstrated the potential to 
boost the detection of key biomolecules by favoring the study of surface-cellular interaction. In fact 
among the current limits of knowledge advancement in oncology the main one is probably related 
to the high sensitivity required to accurately monitor protein-protein interactions, which are relevant 
to follow changes in cellular pathways due to different kinds of external perturbations. Such caveat 
explain why a new quantitative approach based on the nano-immuno-arrays technology, could be 
highly effective in enabling a precise, high throughput and low cost in vitro analysis of tumor cells’ 
lysates, or in vivo studies of their secretome (down to the single cells level).  
Focusing our attention to neuro-oncology we identified the remarkable need for more 
sophisticated diagnostic tools with potential capability of real-time pathological screening and 
subtyping of glial tumors.  
 
1.2 Gliomas 
 
Gliomas (see Fig 1.1) are primary brain tumors classified according to the histological 
classification of the World Health Organization in: Glioblastomas (Grade IV), Anaplastic 
Astrocytomas (Grade III), Low Grade Astrocytomas and Oligodendrogliomas (Grade II). Among 
them the most aggressive ones, namely Glioblastomas and Anaplastic Astrocytomas present an 
incidence of 3.5-2.8 and 0.3-1.2 new cases per 100.000 per year respectively (Ohgaki et al, 2005; 
Deorah et al, 2006).  
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Fig 1.1: T1-weighted MRI image showing a left temporal high-grade glioma 
 
Gliomas are characterized by rapid growth, high level of cellular heterogeneity (see Fig 1.2) 
due to genetic alteration, and infiltrative behaviour, nevertheless those tumors are generally 
confined in the brain parenchyma, and do not show any tendency to bony calvarium or extracranial 
invasion. It is recognized that more complete resections lead to better prognosis, accordingly 
microscopic local resection is the current neurosurgical end point. Despite that, tumor infiltration is 
unfortunately widespread and recurrence may occur near resection margin as well as far away from 
it in both cerebral hemispheres, rarely in the cerebellum and even more rarely in the spinal cord.  
 
 
Fig 1.2: Hematoxylin and eosin stain of a high-grade glioma showing the high degree of cellularity and 
neovascularisation, typical features of those tumors 
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Radiotherapy is therefore central in the treatment of high grade gliomas, since limited field 
fractionated radiation, covering the MRI enhanced lesion as well as peritumoral edema, improves 
patients survival: the standard dose is 60 Gy (Fine et al, 1993).  
Temozolomide (TMZ) received Food and Drug Administration approval in 1999 for 
refractory Anaplastic Astrocytomas, followed by the first line indication for Glioblastoma. The 
international EORTC/NCIC trial in 2005 demonstrated a substantial improvement in median 
survival, representing the first of such improvements since the introduction of radiation therapy in 
the mid-1970s (Stupp et al, 2005). Local intraoperative therapy with antineoplastic wafers 
(impregnated carmustine implants) has demonstrated a further survival advantage although only in 
patients with O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation 
(Westphal et al, 2003; Lechapt-Zalcman et al, 2012). 
To date, complete microscopic excision followed by adjuvant radio- or chemotherapy 
represents the standard of care, nevertheless tumor recurrence generally occurs within few months 
due to the widespread neoplastic infiltration (Smoll et al, 2012). In fact, primary brain tumors 
invade widely spreading single cells anywhere within the brain parenchyma, through infiltration of 
blood vessel walls, subpial glial spaces, or white matter tracts. These mechanisms lead to the 
development of tumor satellites that escape resection and treatment, eventually serving as reservoirs 
for tumor recurrences. Beside parenchymal infiltration, another challenge in the management of 
gliomas is the nearly universal propensity of these neoplasms to present an intratumoral and 
intertumoral molecular heterogeneity allowing tumoral reservoirs to be even more resistent to 
further treatment than the primary lesion (Furnari et al, 2007). 
Despite continuous refinements in therapeutic strategies, the prognosis for patients with 
high-grade gliomas remains dismal, and second-time surgical resection along with local 
intraoperative positioning of antineoplastic wafers represent the only treatment choices for patients 
with recurrent gliomas (Westphal et al, 2003). As a result, the median survival of high-grade 
gliomas is 14-month for patients undergoing surgery plus chemotherapy, and 22-month for those 
treated with surgery plus chemotherapy plus carmustine wafers; so that only 2.2% of patients are 
expected to survive 3 years or more after diagnosis of a Glioblastoma (Ohgaki et al, 2005; Smoll et 
al, 2012).   
 
1.3 GFAP 
 
At present, gliomas are diagnosed by histopathological criteria, and known robust prognostic 
factors for most of these tumors are limited to tumor grade and patient age.  
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While there has been progress in understanding some clinical aspects of these tumors 
(Prados and Levin, 2000; Kitange et al, 2003), new molecular markers are required to better define 
prognosis and response to therapy  
The widespread acceptance that genetic signatures such as losses on chromosomes 1p and 
19q are of prognostic value in Oligodendrogliomas (Cairncross et al., 1998) has spurred interest in 
developing molecular markers to predict outcome and response to treatment across a broader 
population of gliomas. In fact, while numerous genetic alterations have been described in 
Glioblastomas (von Deimling et al, 1995; Watanabe et al, 1996), such markers have proved to be of 
marginal utility in predicting outcome or guiding decisions about disease management.  
Importantly, recent expression profiling studies have revealed that proteomic patterns could 
be of prognostic value (Freije et al, 2004; Nutt et al, 2003), and a systematic review of multiple 
independent proteomic analyses of gliomas published on PubMed since 2008 has demonstrated 
alterations of almost 100 different proteins. Among them we have chosen the Glial Fibrillary Acidic 
Protein (GFAP), a biomarker belonging to the family of intermediate filaments (IF) for our proof of 
concept.  
 
 
Fig 1.3:  Fluorescent micrographs (red stains for GFAP+ astrocytes, whereas turquoise and green stain for 
oligodendrocyte O4 and β-tubulin markers respectively) showing high-grade glioma cells growing as: a) 
spheres in culture (more aggressive behavior), b) monolayer in culture (better differentiated tumors).  
Photos from: North Central Cancer Treatment Group at Mayo Clinic (USA) 
 
Firstly isolated, characterized and described by Lawrence F. Eng in 1969, GFAP is a type III 
IF protein that maps in humans to 17q21 (Bongcam-Rudloff et al, 1991; Eng et al, 2000). Being 
closely related to its non-epithelial family members, such as vimentin, desmin, and peripherin, 
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which are all involved in the structure and function of the cell’s cytoskeleton, GFAP is thought to 
help maintaining astrocytes’ mechanical strength and shape.  
Noteworthy, GFAP is necessary for many critical roles in the central nervous system (CNS): 
it is pivotal during mitosis, as confirmed by the increase in the amount of phosphorylated GFAP 
during this phase of cellular life, it plays a role in astrocyte-neuron interactions as well as cell-cell 
communication, and has been linked to multiple degenerative processes including abnormal 
myelination, white matter structure deterioration, and functional/structural impairment of the blood–
brain barrier (Liedtke et al, 1996).  
Finally, GFAP is a potentially informative plasma biomarker for gliomas being detected in 
plasma samples of every patient with high-grade glioma (Husain et al, 2012). Because of its role in 
cell’s differentiation, only well differentiated cells retain the ability to express it (see Fig 1.3), while 
the most aggressive ones lose this typical feature at a certain point in their dedifferentiation process 
(Singh et al, 2003). 
Beside GFAP, other proteins of interest are now being advocated for early diagnosis or 
monitoring of glioma. To this regard collection or panels of such proteins as opposed to a single 
biomarker will be necessary for a reliable diagnostic improvement in terms of accuracy (Rasooly et 
al, 2006). In general, to realize the full potential of clinical biomarkers, new bioanalytical 
technologies are being developed with the aim to achieve an accurate detection at low volumes (till 
to pg/ml) of panels of biomarkers (Kingsmore et al, 2006)  
 
1.4 From Micro- to Nanobiosensors for protein recognition: 
state of the art 
 
A biosensor is a device that combines a biological component with a physicochemical 
detector used for the recognition of an analyte at a micro- or nanoscale. An indispensable 
requirement for any biosensor is an excellent specificity and sensitivity for biomarkers detection, 
the former can be defined as the ability of the assay to rule out a condition when a specific 
biomarker is absent, while the latter is defined as the ability of the assay to identify a condition 
when it is present (Rusling et al, 2010). Those clinical specificity and sensitivity parameters are 
closely linked to the method used for measurements, and need to be high (>90%) to avoid false 
positive or false negative results (Moncada et al, 2008).    
The sensitive biological elements of biosensor, generally represented by biologically derived 
materials or biomimetic components (i.e. tissue, microorganisms, enzymes, antibodies, nucleic 
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acids, etc.), interact throughout specific binding to, or recognition of, the analyte under study. The 
detector element or transducer, which works in a physicochemical way (i.e. optical, piezoelectric, 
electrochemical, etc.), transform the signal resulting from the interaction of the analyte with the 
biological element into another signal that can be more easily measured and quantified.  
Detection elements play a key role in analyte recognition in biosensors: therefore detection 
elements with high analyte specificity and binding strength are required. While antibodies (Abs) 
have been increasingly used as detection elements in biosensors, some key challenges remain: their 
immobilization on the biosensor surface and the optimal method for identifying the antigen-
antibody interaction.  
According to the array-based optical, mass-detection or radio-labeled read out, micro and 
nanobiosensors can be classified as follows: 
 
1.4 a) Optical read-out 
 
Optical biosensors account for the most known and widespread devices and protocols for 
detection of bioanalytes, including enzyme-linked immunosorbent assay (ELISA), which is 
particularly useful for a plate-based detection and quantification of substances such as peptides, 
proteins, antibodies and hormones.  
In an ELISA assay, an antigen must be immobilized to a solid surface and then complexed 
with an antibody that is linked to an enzyme; the detection is accomplished by assessing the 
conjugated enzyme activity via incubation with a substrate to produce a measureable product, which 
generally is a detectable fluorescence signal. Therefore the most crucial element of the detection 
strategy is a highly specific antibody-antigen interaction.  
ELISAs are typically performed in polystyrene plates, which will passively bind Abs and 
proteins; having the reactants of the ELISA immobilized to the microplate surface makes it easy to 
separate bound from nonbound material during the assay. This ability to wash away nonspecifically 
bound materials makes the ELISA a powerful tool for measuring specific analytes within a crude 
preparation. 
ELISAs can be performed with a number of modifications to the basic procedure (see Fig 
1.4): the key step, immobilization of the antigen of interest, can be accomplished by direct 
adsorption to the assay plate or indirectly, via a capture antibody that has been attached to the plate. 
The antigen is then detected either directly (labeled primary antibody) or indirectly (labeled 
secondary antibody). 
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 The most powerful ELISA assay format is the sandwich assay. This type of capture assay is 
called a “sandwich” assay because the analyte to be measured is bound between two primary Abs: 
the capture antibody and the detection antibody.  
The sandwich format is often the preferred one because it is more robust and equally 
sensitive then direct or indirect assays.  
 
 
Fig 1.4: Schematic representation of the most common ELISA formats.  
Drawing from: Thermo Fisher Scientific Inc 
 
ELISA is nearly always performed using 96-well or 384-well polystyrene plates and 
samples in solution (i.e., biological fluids, culture media or cell lysates); however, other variants of 
ELISA exist: 
- ELISPOT (enzyme-linked immunospot assay) refers to ELISA-like capture and 
measurement of proteins secreted by cells that are plated in polyvinylidene difluoride 
(PVDF)-membrane-backed microplate wells. It is a "sandwich" assay in which the 
proteins are captured locally as they are secreted by the plated cells, and detection is with 
a precipitating substrate. ELISPOT is like a Western blot in that the result is spots on a 
membrane surface (Czerkinsky et al, 1983) 
- In-cell ELISA is performed with cells that are plated and cultured overnight in standard 
microplates. After the cultured cells are fixed, they undergo a permeabilization and 
blocking processes, and finally target proteins are detected with Abs. This is an indirect 
assay, not a sandwich assay. The secondary Abs are either fluorescent, for direct 
measurement by a fluorescent plate reader or a microscope; or enzyme-conjugated, for 
detection with a soluble substrate using a plate reader. 
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1.4 b) Radio-labeled read-out 
 
The measurement of radiolabels by scintillation counting has long been one of the most 
reliable methods for accurate, quantitative measurement in biochemical experiments (Lees et al, 
1999).  
Today it has been supplanted by the ELISA method, where as previously said the antigen-
antibody reaction is measured using colorimetric instead of radioactive signals; however, because of 
their robustness, consistent results and relatively low price per test, radio-ladeled read-out methods 
are again becoming popular (Godovac-Zimmermann et al, 2005). 
The concepts of radio-labeled read-out have been employed in the context of proteomics, 
where they offered gains in absolute sensitivity and dynamic range: for instance multi-photon 
detection methodology, proposed as a tool to routinely and quantitatively detect radioactive labels 
on two-dimensional gels, has several characteristics that are advantageous for functional protein 
detection (Kleineret al, 2008):  
- First of all, by using single particle detectors, the sensitivity for detection of radiolabels 
can be improved dramatically;  
- Secondly, because single particle detectors can differentiate the particle energies 
produced by different decay processes, it is possible to choose combinations of 
radioisotopes that can be detected and quantified individually on the same 2D gel; 
- Thirdly, this technology is essentially linear over 6 to 7 orders of magnitude (i.e. it is 
possible to accurately quantify radiolabeled proteins over a range from at least 60 
zeptomoles to 60 femtomoles).  
In principle, the implementation of chemical radiolabeling  methods could provide a 100-
fold decrease in the amount of biological material needed for proteomics experiments, while 
reducing imaging times 10–100-fold, with total amounts of radioactivity far below legal limits 
(Kleineret et al, 2008). 
Overall, the quest for ultra-high sensitivity and quantitative precision is providing new 
impetus to proteomics studies: both micro- and nanoarrays hold the promise of high selectivity and 
sensitivity, ease of use reasonable costs per assay and good possibilities for future automation. 
Nevertheless several drawbacks still limit the diffusion of radio-labeled read-out: the most 
important ones are certainly related to the special facility, precautions and licensing required: since 
radioactive substances are used a gamma counter is essential to measure the radiations emitted by 
the radionuclide, while security issues impose strict protocols for their stocking and disposal.    
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1.4 c) Mass-detection read-out 
 
Mechanical interactions are fundamental to biology, in fact on one hand mechanical forces 
of chemical origin determine motility and adhesion on the cellular scale, and govern transport and 
affinity on the molecular scale; on the other biological sensing in the mechanical domain provides 
unique opportunities to measure forces, displacements and mass changes from cellular and 
subcellular processes (Arlett et al, 2011).  
The advances in micro- and nanofabrication technologies have enabled the preparation of 
increasingly smaller mechanical transducers, so that nowadays a promising family of biosensors is 
represented by micro- and nanomechanical systems, which are basically cantilever-like sensors: 
they are particularly well matched in size with molecular interactions, and provide a basis for 
biological probes with single-molecule sensitivity, indeed (Yang et al, 2006; Zougagh et al, 2009). 
Recently, detection of mass in the zeptogram range and sensitivity in liquid to the fraction of nM 
concentration in real time has been demonstrated (von Muhlen et al, 2010). 
Despite biosensors based on nanomechanical systems have gained considerable relevance in 
the last decade, several theoretical and experimental studies, reporting the influence of the mass 
transport on antibody biosensors as a function of analyte concentration and incubation time, 
concluded that pushing the sensitivity to the limit of single molecule detection may not bring the 
expected benefit to the overall performance (Nair et al, 2006; Sheehan et al, 2005).  
In fact mass transport can significantly lower the practical sensitivity of a device by 
reducing the number of binding events (Tamayo et al, 2013). Moreover, especially at low 
concentration, which is typical of biomolecular experiments, the interaction between target 
molecules and the biosensor can play as critical a role as the chemical reaction itself in governing 
the binding rate (Kusnezow et al, 2006). 
In the attempt to overcome these limitation Melli and colleagues developed a 
micromechanical sensor (see Fig 1.5) based on vertically oriented oscillating beams (or pillars) 
which make it possible to locate the sensitive area at the free end of the oscillators (Melli et al, 
2011). 
 Practically, an array of such pillars (3μm x 8μm in plane, and 15μm in height) behaves as 
an array of isolated nanosized sensors embedded in a quasi-infinite analyte solution: while the top 
face of the pillars represents the nanosized active area, the pillars themselves can be operated as 
mass detectors. In particular these three-dimensional structures with dimensions comparable to the 
diffusion length of the target molecules have proved to increase the reaction speed by 3 orders of 
magnitude, while attaining improvement also in concentration sensitivity.  
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Fig 1.5: Micromechanical pillars. Photo from: Melli M et al, ACS Nano 2011 
 
 
1.4 d) Mechanical-sensing read-out 
 
To conclude this digression on micro- and nanobiosensors it is also useful to cite that in the 
last decade, the quest for protein detection in smaller volumes, along with continuous efforts to 
monitor specific interactions between Abs and antigens employed in an immunoassay system have 
led to the development of several ELISA like biosensors, including Atomic Force Microscopy 
(AFM) based arrays.  
AFM is a very high-resolution type of scanning probe microscopy, consisting of a cantilever 
with a sharp tip (probe) at its end that is used to scan the specimen surface, a laser to measure any 
probe deflection and reflect it from the top surface of the cantilever into an array of photodiodes; 
the tip-sample intermolecular forces are detected, as a function of the distance between the two 
(Picas et al, 2012).  
The AFM can be operated in a number of modes, depending on the application: basically 
AFM imaging may be divided into static mode (also called contact) and a variety of dynamic modes 
(non-contact or "tapping") where the cantilever is oscillated. The stiffness of the cantilever 
determines the ratio between the distance moved and the force exerted by the surface, therefore this 
parameter is most relevant for determining the tip-sample interaction during the majority of AFM 
operation modes. 
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Fig 1.6: Schematic illustration of the AFM: the tip is attached to a cantilever, and is raster-scanned over a 
surface. The cantilever deflection due to tip-surface interactions is monitored by a photodiode sensitive to 
laser light reflected at the tip backside; the position of the reflected beam is kept centered in the diode 
through feedback-controlled z-changes in the stage.  
Drawing from: Dept of Pharmaceutical Physical Chemistry, Uppsala University (Sweden) 
 
For instance while medium stiffness cantilevers are well suited for patterning of surfaces 
(i.e. nanografting); on the other hand, since to obtain quality images it is critical that the AFM tip 
not damage the surface being scanned, softer cantilevers (< 0.04N/m) allowing to image surfaces 
with very low forces, are the most indicated to avoid undesirable surface modifications.  
AFM is a powerful technique for investigating surfaces by visualizing their topographic 
characteristics: even very low number of target molecules can be reliably detected using height 
and/or compressibility measurements. Starting from the works of Liu and colleagues it has been 
consistently demonstrated that accurate height measurements of nanopatches before and after 
sequence specific hybridization of DNA oligomers allow for reliable, sensitive and label-free 
detection of hybridization itself (Liu et al, 2005; Liu et al, 2008, Mirmomtaz et al, 2008).   
Moreover, AFM probes may also be functionalized: in 1997, Allen and colleagues were the 
first to use AFM probes functionalized with ferritin to monitoring the adhesive forces between the 
probe and anti-ferritin antibody-coated substrates (Allen et al, 1997).  
Recently, Volkov and colleagues demonstrated that a reliable reading of the immunosignal 
(a suggested dimensionless combination of brush length and grafting density) can be obtained from 
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an area as small as ∼3μm2: approximately 4 million times smaller compared to typical ELISA 
sensors (Volkov et al, 2010). Intriguingly, they found that AFM could reliably distinguish between 
having the immunosignal from either antibody and from both Abs together: attaining a new 
detection limit that was impossible to obtain by using standard optical methods. 
 
1.5 Micro- and Nanofabrication strategies: overview 
 
The basic concept of several techniques for fabrication and biopatterning of surfaces at the 
micro- and nanometer scale, including photolithography, microcontact printing, dip pen 
nanolithography, AFM nanografting will be described in the following pages. To conclude, special 
attention will be drawn to the DNA-directed immobilization (DDI), a bottom up 
biofunctionalization technique particularly suitable for a high-sensitivity determination of panels of 
biomarkers.  
 
1.5 a) Photolithography  
 
Photolithography is a very cost-effective process used in microfabrication to pattern thin 
films: in other words it allows to transfer a geometric pattern from a photomask to a light-sensitive 
chemical photoresist on the substrate. A series of chemical treatments is then used to enable 
deposition of a new material in the desired pattern upon the material underneath the photoresist.  
Photolithography enables scientists to create extremely small patterns (down to a few tens of 
nm in size), while maintaining exact control over the shape and size of the objects created.  
Photolithography requires a clean room and combines several steps in sequence (see Fig 1.7) 
for the microfabrication of masters and the subsequent process of replica molding of the masters in 
poly-dimethylsiloxane (PDMS).  
- Organic or inorganic contaminations are firstly removed by wet chemical treatment 
(generally with solutions containing hydrogen peroxide) and wafers are used as 
substrates to fabricate the master molds.  
- The wafers are then heated to a temperature sufficient to drive off any moisture that may 
be present on their surface, and covered with the photoresist by spin coating. 
Immediately after spinning, the wafers must be baked to drive off excess of photoresist 
solvent, and afterwards exposed to a UV dose of 375 to 240mJ/cm
2
 (depending on the 
thickness of the SU 8) on a contact aligner.  
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Fig 1.7: Microfabrication process: PDMS prepolymer is poured onto a photolithographically patterned 
master; after curing PDMS is peeled away and microwells are ready to be functionalized  
for deposition of living cells. Drawing adapted from: Dept Biomedical Engineering, UCIrvive (USA) 
 
- The masters are further treated to render the exposed surface very inert, which facilitate 
the release of the PDMS mold after curing.  
- The PDMS is ready to be degassed and poured onto the master, then degassed again and 
cured in a 65° oven for 1 to 16h. Once cured, the PDMS is manually peeled off the 
master, and the resulting structure (i.e. the microwells) are ready to be functionalized.  
 
1.5 b) Microcontact Printing 
 
For a while photografting of proteins was obtained from classical photolithographic 
techniques; in 1993 a novel approach, called microcontact printing, was introduced by Whitesides 
and colleagues for patterning SAM of alkanethiols onto gold substrates (Kumar et al, 1993; López 
et al 1993).  
To date, microcontact printing is widely used for generating micropatterns of nanomaterials 
such as organic molecules and biomolecules over large surface areas (>cm2). In the microcontact 
printing process, a microstructured elastomer stamp is coated with a solution of a nanomaterial and 
applied to a substrate of choice, then after a given period of time in conformal contact (generally 
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overnight), the stamp is removed leaving a replica of the stamp pattern on the substrate surface (see 
Fig 1.8).  
The elastomer stamps are made typically from PDMS by curing liquid prepolymers of 
PDMS on a lithographically prepared master. The elastomeric properties of stamps made of PDMS 
ensure conformal contact (intimate contact) with various substrates.  
 
 
Fig 1.8: Scheme of microcontact printing: a conventionally fabricated PDMS stamp serves as the vehicle to 
transfer the ink of choice, in this case proteins, upon brief contact; then the transfer of those proteins occurs 
only at the sites of conformal contact between stamp and substrate. 
Drawing from: Bernard A et al, Adv Mater 2000 
 
As the stamps can be structured with almost any pattern, conformal contact can be achieved 
in many different geometrically conformed ways.  
Moreover, since this technique is carried out under room temperature, different 
biomolecules may directly be transferred in a controlled way onto a variety of substrates while 
retaining their biological activity. However the deposition of liquid samples followed by drying 
could be very complex, leading to ill-defined patterns, protein aggregation and loss of biological 
activity.  
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Noteworthy, this problem has recently been overcame by extending these concepts to the 
nanoscale dimensions in a process referred to as nanocontact printing, so that, features as small as 
40nm can now be fabricated by this way (Li et al, 2003). Nanocontact printing has been achieved 
by decreasing the feature sizes in the PDMS stamp and diluting the nanomaterial inks, utilising 
special variants of PDMS stamps or employing new polymeric material stamps. Another important 
factor on obtaining high resolution prints at the 100nm level relates with the ink utilised, to this 
regard biomolecules are attractive nanocontact printing inks since their high molecular weight 
prevents diffusion during the printing step, resulting in high-resolution features.  
As opposed to the parallel conventional photolithographic process, nanocontact printing is 
not diffraction limited and makes possible to pattern surfaces with molecular sized features. A 
significant advantage of nanocontact printing lithography compared to serial techniques such as dip-
pen nanolithography (DPN) is that large areas can be nanopatterned rapidly.  
Nevertheless, multicomponent biomolecule nanopatterning is still very problematic with this 
technology due to the practical difficulties in accurately aligning multiple flexible stamps over a 
large area while maintaining a nanoscale resolution, and thus further development is required to 
solve this problem. 
 
1.5 c) Dip Pen Nanolithography 
 
While studying a process through which molecules could be transferred to a wide variety of 
surfaces to create stable chemically-adsorbed monolayers in a high resolution lithographic process, 
Mirkin and colleagues termed DPN a scanning probe lithography technique where an AFM tip was 
used to transfer alkane thiolates to a gold surface (Mirkin et al, 1996; Piner et al, 1999).  
DPN allows surface patterning on scales of under 100nm, and is the nanotechnology analog 
of the dip pen (also called the quill pen), where the tip of an AFM cantilever acts as a "pen," which 
is coated with a chemical compound or mixture acting as an "ink," and put in contact with a 
substrate, the "paper." DPN enables direct deposition of nanoscale materials onto a substrate in a 
flexible manner.  
Recent advances have demonstrated massively parallel patterning using two-dimensional 
arrays of 55,000 tips. Applications of this technology currently range through chemistry, materials 
science, and the life sciences, and include fabrication of ultra high density biological nanoarrays 
(Chai et al, 2011). 
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1.5 d) AFM Nanografting 
 
Nanopatterning of surfaces for biomedical applications has been of growing interest in 
recent years, from both scientific and technological points of view: indeed diverse biological and 
medical applications can be envisioned such as biochips and biosensors.  
To this regard nanotechnology not only offers the reward of smaller dimensions with more 
reaction sites, but also smaller test sample volumes and potentially higher sensitivity and 
throughput screening for molecular diagnostics.  
Beside its uses as imaging tool, the AFM can also be exploited for a fine nanopatterning of 
surfaces: if compared to other methods of nanofabrication, nanografting allows more precise control 
over the size and geometry of patterned features and their location on the surface. The technique of 
nanografting is usually used on self assembled monolayers (SAMs) and is achieved in the presence 
of a second replacement surfactant molecule with a greater affinity for the surface, or concentration 
in the grafting solution than the molecule being removed by the AFM tip (see Fig 1.9). Therefore, 
once the pre-formed SAM is removed from the desired area by the AFM tip, it will be replaced with 
a second surfactant to form a new SAM in the patterned area.  
 
 
Fig 1.9: Representation of AFM based nanografting: once the pre-formed SAM is removed from the desired 
area by the AFM tip, it will be replaced with a second surfactant to form a new SAM in the patterned area. 
Drawing from: Xu S et al, Langmuir 1997 
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Noteworthy, some criteria need to be met: the SAM must be readily removable with the 
force applied by the AFM tip, but more importantly, the second surfactant must form the new SAM 
rapidly. It is for these reasons that thiol SAMs on gold are usually the system of choice for 
nanografting experiments, due to the way in which thiols rapidly form homogenous monolayers on 
exposed gold surfaces. This strategy may be used for the production of nanometer-sized protein 
patterns on gold surfaces by exploiting the affinity of biomolecules towards different SAMs (Liang 
et al, 2012). 
AFM based lithography methods are attractive nano-arraying techniques and have shown 
many potentialities in generating arrays with significantly reduced amount of capture materials, 
such as DNA, peptides and Abs. Further, these methods exploit the AFM tip (radius of curvature 
below 10nm) to selectively pattern complex structures on the surface and can offer high sensitivity 
and resolution.  
By varying fabrication parameters, as the number of scanning lines at high tip load set in a 
given surface area, the speed of the AFM tip, the concentration of molecules in solution, etc the 
numbers of molecules released to the surface can be appropriately tuned. In the pioneering work of 
Mirmomtaz, our group showed that by nanografting DNA nanostructures patches of predetermined 
different height could be reproducibly created (Mirmomtaz et al, 2008).  
Moreover recent investigations demonstrated the correlation between patch height and DNA 
molecules surface density in the range of 10
12
 - 3x10
13
 mol cm
-2
 (Castronovo et al, 2011; Bosco et 
al, 2012)  
The great advantage of AFM patterning is that the same technique may be used for both 
patterning and imaging a SAM as several physical and mechanical properties can be measured all at 
once.  
The topographic height of the patches is used to infer any change at any step of the 
nanoassay, and, concertedly with the measurement of the roughness, within and outside the patch, 
constitute a unique method not only to quantify the bio-recognition events, but also to rule out the 
presence of unspecific molecular adsorption. 
Other advantages of this technique include (Bano et al, 2009; Sanavio et al, 2010):  
- the possible identification of molecular orientation by measuring the molecular height 
with high precision (order of Angstroms) with respect to a supporting substrate,  
- the well defined patterning of homogeneously oriented molecules,  
- the possibility of printing multiple features in array format, where different molecules 
are placed selectively at different sites.  
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1.5 e) DNA-Directed Immobilization 
 
Diagnostic immunoassays and DNA sensing are driving efforts to miniaturize biological 
assays and to conduct them in parallel; specifically, DNA-based arrays are becoming the leading 
technology for high integration and miniaturization of bioassays (Schena et al, 1995; Bernard et al, 
2000).  
The use of DNA microarrays technology for proteomics known as DDI was introduced in 
1994 by Niemayer and colleagues showing that covalent DNA-streptavidin conjugates could be 
utilized for the reversible and site-selective immobilization of various biotinylated enzymes and 
antibodies (Niemayer et al, 1994).  
Their pioneering experiments demonstrated that enzymes, such as biotinylated alkaline 
phosphatase, beta-galactosidase, or horseradish peroxidase, as well as antibodies, such as 
biotinylated anti-mouse or anti-rabbit immunoglobulins, could be coupled to the DNA-streptavidin 
adapters by simple, two-component incubation, and that the resulting preconjugates could be 
exploited to hybridize complementary oligonucleotides by surface-bound (Niemayer et al, 1999; 
Niemayer, 2002; Niemayer, 2012).  
DDI proceeds with a higher immobilization efficiency than conventional immobilization 
techniques because of the reversible formation of the rigid, double-stranded DNA spacer between 
the surface and the proteins.  
The simultaneous immobilization of different compounds using microstructured 
oligonucleotide arrays as immobilization matrices demonstrates that DDI proceeds with site 
selectivity due to the unique specificity of Watson-Crick base pairing; moreover, it allows for a 
reversible functionalization of the sensor surfaces with the proteins of interest.  
Since DDI technologies and DNA nanoconstruction essentially depend on similar pre-
requisites, which in particular are: large and uniform hybridization efficiencies, combined with low 
nonspecific cross-reactivity between individual sequences, this microarray approach has emerged 
along the last years as a promising tool for chip-based immunoassay meant to multiplex antigen 
detection.  
In fact, it is well known that the self-assembly of semi-synthetic DNA-protein conjugates in 
so called nano-assembled monolayers (NAMs) makes it easy to generate unlimited reproducible,  
configurable nanoarrays exploiting precise and reliably proteins/Abs detection methods (see Fig 
1.10).  
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Fig 1.10: Schematic representation of the three steps involved in DDI: A) ssDNA grafting, B) immobilization 
of the antibody of interest by hybridization with the  complementary strand of DNA, C) immobilization of the 
protein of interest.  Drawing adapted from Sanavio B et al, ACS Nano 2010 
 
DDI allows for highly economical use of antibody materials (at least 100-fold lower than the 
amount needed for preparing an array by direct spotting), therefore taking into account the greater 
versatility and convenience of handling of the self-assembly approach, DDI proved to be an 
advantageous alternative to conventional techniques for generating versatile and robust protein 
arrays.  
The DDI strategy bears the potential for relatively rapid high sensitivity determination of 
limited panels of biomarkers with good precision and accuracy.  
Despite its potential to revolutionize protein diagnostics, the major problems in the 
fabrication of such antibody arrays concern the initial efforts required to reproduce homogeneously 
the attachment of the antibody on the DNA substrate.  
To this regard, protein recognition could eventually be carried out in a single step by directly 
grafting the double strand DNA already bound with the antibody of interest onto the SAM, such 
advancement could significantly reduce both the procedural steps needed and relative handling 
time, as well as the costs of analysis in the near future. 
 
1.6 Aim of the research 
 
In this research we have chosen to exploit all the potentialities of microfrabrication, 
nanofunctionalization and imaging described in the previous pages to develop a new diagnostic tool 
(see Fig 1.11).  
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Fig 1.11: Schematic representation of the device.  
Drawings adapted from Bano F et al, NanoLett 2009 
 
In fact, to fulfil the abovementioned goal of enabling a precise, high throughput and low cost 
in vitro analysis of tumor cells’ lysate, or, in vivo studies, also of their secretome, down to the single 
cells level, we developed a device consisting in micro-fabricated wells capable to isolate and host 
living astrocytes (ideally, one cell per micro-well).  
 
 
Fig 1.12: Schematic drawing of the cells immobilized in each microwell and faced to the 
functionalized nano-immuno arrays 
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Beside tailoring the processes of microfabrication to create wells suitable for hosting living 
cells, the utmost attention was paid to the optimization of the multiple steps required to 
functionalize those microwells: an indispensable pre-requisite for enabling cell adhesion, especially 
when dealing with eukaryotes.  
Then, to create an effective biosensor, able to detect in such small volumes the presence of 
the proteins of interest, ideally for multiplexing assays and meant to fit within the small dimensions 
of this microdevice, we challenged the optimization of protocols for immobilization of antibodies 
onto surface tethered, spatially constrained DNA patches.  
Accordingly, we prepared nanosized immuno patches specific for the recognition of GFAP 
on a SAM of top-terminated oligo-ethyleneglicol alkanethiol-modified (TOEG) gold surface, in 
order to use the solid matrix with nanopatches as the ceiling of each microwell (see Fig 1.12). 
Toward this path, we focused toward the sensitivity implementation of the nanobiosensor, and tried 
to achieve that of current benchmark assays such as ELISA.  
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2.1 Fabrication and functionalization of microwells 
 
Microwells were obtained from a membrane of PDMS, by spin coating and replica molding 
(see Fig 2.1) from a reusable master with positive pillar-like relief structure (traditional 
photolithography using photoresist SU8 forms).  
 
 
Fig 2.1: Schematic representation of microwells’ fabrication 
 
The functionalization of the floor and the walls of each well was obtained by staining the 
PDMS structure with a polyornithine solution (0.01% of polyornithine plus 5% of lucifer yellow) 
for 1h at room temperature. The excess of polyorthinine outside each microwell was removed 
through microcontact printing run overnight in order to clean up the PDMS within the wells. 
Aiming to test the feasibility of living cells patterning within the PDMS microwells, a series 
of tests were conducted with different cells populations:  
- On a first series of experiments the ability of prokaryotes, such as E.Coli (kindly 
provided by Structural Biology Lab @ Elettra), to adhere and survive with and without 
administration of growth medium, for at least 1h, within the microwells was tested. 
- Subsequently a similar set of experiments was conducted in order to understand whether 
complex and fragile eukaryotes, such as hyppocampal cells (kindly provided by Spinal 
Biophysics Lab @ UniTS), could adhere and survive onto a PDMS surface with or 
without functionalization with polyornithine.    
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2.2 Immobilization of antibodies 
 
For the fabrication of nanoarrays, meant to immobilize Abs specific for the protein of 
interest (i.e. GFAP), an approach based on AFM nanografting techniques was applied. Whilst it 
would be ideally desirable to directly functionalize a biosensor’s surface with specifics Abs, the 
chemical modification to which they would be subject could affect their specificity; therefore it is 
still complex presently to avoid intermediate steps for Abs immobilization.  
To this regard, the most common strategy is to exploit the high affinity of the streptavidin-
biotin binding, working with commercially available biotinylated Abs (see Fig 2.2).  
 
Fig 2.2: Schematic exploitation of the biotin-streptavidin affinity  
for specific immobilization of biotinylated Abs 
 
Two main strategies were adopted: the first one based on fabrication of NAMs of biotin-
streptavidin complexes; the others based on optimized DDI strategies.  
 
2.2 a) Fabrication of patches of biotin terminated alkanethiol 
 
Nanosized patches of biotin terminated alkanethiol were prepared by tip-assisted AFM 
nanografting inside a matrix of SAM of alkanethiol-modified gold surfaces; then streptavidin (STV) 
was exploited to recognize the biotin and act as an antibody binding protein for biotinylated Abs.  
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STV (see Fig 2.3) is a protein extensively used in molecular biology and bionanotechnology 
due to its extraordinarily high affinity for biotin (Kd = 10
-14
 to 10
-15
M), and the strong streptavidin-
biotin complex's resistance to organic solvents, denaturants, detergents, proteolytic enzymes, and 
extremes of temperature or pH (Deng et al. 2012).  
 
 
Fig 2.3: Tetrameric structure of Streptavidin. Drawing modified from Protein Data Bank 
 
STV in its tetrameric structure presents 4 biotin binding sites, which can be exploited to both 
recognize the nanosized patches of biotin terminated alkanethiol, and subsequently to immobilize 
biotinylated monoclonal GFAP Abs on top of them (see Fig 2.4).  
 
 
Fig 2.4: Schematic representation of the three steps involved in the fabrication of patches of biotin 
terminated alkanethiol: A) biotin grafting, B) hybridization of the NAM of biotin with STV and subsequent 
immobilization of biotinylated Abs, C) recognition of the protein of interest 
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A commercial AFM (Park XE-100) was utilized to obtain small patches, sized 1μm x 1μm, 
with an inter-patches distance of at least 2.5μm. Nanografting was conducted in a solution of biotin 
5μl (50mM) in H2O plus ethanol 150μl.  
The biotin patches were obtained promoting the replacement of the TOEG6 molecules with the 
biotin terminated alkanethiol by scanning the predetermined area of 1μm x 1μm with cantilever 
characterized by a stiffness of 0.6 N/m (NSC 19 MikroMasch).  
During nanografting the tip was always applied at a large force (about 100nN) with a scan rate 
of 2000nm/s.  
- This first grafting step was followed by a three series of washing with 
Tris(hydroxymethyl)aminomethane-Ethylene-diamine-tetraacetic acid (Tris-EDTA or 
TE) buffer to remove any physically adsorbed molecules before the start of the imaging 
session. 
- The second step consisted in the incubation of the NAMs of biotin with STV by specific 
linking, obtained at the concentration of 500pM in Phosphate Buffered Saline (PBS) and 
an incubation time of 1h at room temperature.  
Even this second step was routinely followed by a thorough SAM washing (3 times with 
PBS) before conducting the subsequent analysis of the sample by means of AFM 
topographic height imaging. 
- The third step consisted in the immobilization of the biotinylated monoclonal GFAP Abs 
onto the nanopatches (Synaptic System). A solution of 100μl of PBS containing GFAP 
Abs (Synaptic System) was incubated over the NAM for 1h at room temperature with a 
dilution ratio of 1:100.  
After a routine washing of the SAM, repeated for three times in a row with PBS the 
NAMs’ height finally achieved was measured by the standardized AFM topographic 
analysis performed after each previous step. 
 
2.2 b) Preparation of DDI of biotinylated antibodies 
 
Multiple NAMs of thiol modified single strand DNA (ssDNA) were prepared by AFM-
based nanografting inside a matrix of SAM of TOEG3 or TOEG6 surfaces.  
Subsequently the preparation of multiple nanopatches, meant to act as bionanosensors, was 
obtained by optimizing the previously described DDI strategy (see Fig 2.5). 
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Fig 2.5: Schematic representation of the three main options to immobilize biotinylated antibodies 
onto DDI fabricated NAMs: the cDNA utilized to covalently bind to the ssDNA may be functionalized with a 
tyrosine binder-tag, necessary for the subsequent conjugation with STV, or directly with a STV-tag 
 
The size of each patch was 1μm x 1μm, whereas the inter-patches distance chosen was 2.5 
μm. Nanografting was conducted in a solution of NaCl 1M with various strands of DNA modified 
with a thiol linker, (CH2)6SH (also named C6), at the 3’ termination. The length of the C6 linker is 
about 1.2nm. C6 has the double function to link covalently the DNA to the gold surface while 
making the DNA molecules away from the same surface and available to hybridization with the 
complementary strand.  
Three different strands of ssDNA were utilized: 
- cF4: 5’-ctt att tta ttg tta tac gcc c-3’ and its cDNA conjugated with a tyrosine binder-tag,  
- cF9: 5’-ctt gat tgc cac ttt cca c-3’ and its cDNA already conjugated with a STV-tag, 
- cF5: 5’-ctt atc tta tga ccg gac c-3’ and its cDNA already conjugated with a STV-tag. 
The concentration of ssDNA utilized in each set of experiments was 5μM in TE buffer 1M 
NaCl; the DNA patches were obtained promoting the replacement of the TOEG molecules with the 
oligonucleotides by scanning an area of 1μm x 1μm with the AFM tip applying a large force (about 
100nN) with a scan rate of 2000nm/s. TOEG is composed by an alkanethiol with 16 carbons plus 6 
(TOEG6) or 3 (TOEG3) ethyleneglicol units, noteworthy the former is much more water soluble 
than the latter, making it easier for the TOEG6 to be removed during the nanografting procedure by 
varying the fabrication parameter (number of scanning lines in a given surface area).  
- This first grafting step was followed by a three series of washing with TBS to remove 
any physically adsorbed molecules before the start of the imaging session.  
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- The second step consisted in the hybridization of the NAM of ssDNA patches with their 
complementary DNA strands (cDNA) by sequence specific DNA linking. The 
hybridization was conducted at the concentration of 500nM in TE buffer 1M NaCl with 
an incubation time of 1h at room temperature. Even this second step was routinely 
followed by a thorough SAM washing, 3 times with Tris Buffered Saline (TBS), before 
conducting the subsequent analysis of the sample by means of AFM topographic 
imaging.  
- The third step consisted in the immobilization of the antibodies specific for the chosen 
protein of interest (always GFAP) on the top of the NAMs with or without blocking 
buffer solutions. Blocking buffer solutions are routinely used during antibody staining 
procedures (i.e. Western Blotting, direct and sandwich ELISA assays or immune-
histochemistry-based protocols) to reduce background or unspecific staining; for the 
purposes of this experimental session two different blocking solutions were tested: Skim 
Milk Powder in TBS blocking buffer or BSA blocking buffer. 
 As in the experimental session with patches of biotin terminated alkanethiol, biotinylated 
monoclonal GFAP Abs (Synaptic System, GmbH) were tested onto the nanopatches. A solution of 
100μl of blocking buffer containing GFAP Abs at a dilution of 1:100 was incubated over the SAM 
for 1h at room temperature. After a routine washing of the SAM, repeated for three times in a row 
with TBS (set of experiments without blocking buffer) or TBS containing 0.05% Tween 20 (TBST) 
plus three more times with TBS (set of experiments with blocking buffer), the NAMs’ height 
afterward achieved was measured by AFM topographic analysis to confirm the immobilization of 
the GFAP Abs onto the NAMs.  
 
2.3 Immobilization of GFAP  
 
Aiming to further characterize a protocol suitable for multiplexing analysis, the series of 
experiments with DDI of biotinylated Abs were the only ones finally brought to the next level of 
protein immobilization.  
 
2.3 a) Immobilization of GFAP in PBS 
 
To avoid risks of unspecific bindings, the immobilization of GFAP onto the NAMs was 
initially conducted only by incubation with recombinant GFAP (Synaptic System) at a 
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concentration of 40nM for 1h at room temperature in a solution of blocking buffer. The subsequent 
AFM imaging was performed after three washes with TBST followed by three more washes with 
TBS.  
   
2.3 b) Immobilization of GFAP in multicells’ lysate 
 
The suitability of those nano-immuno arrays to selectively recognize GFAP in the cells’ 
lysate, which contains several different proteins potentially responsible for unspecific bindings over 
the NAMs or over the surrounding SAM, was finally tested by incubation of the SAM in a solution 
of 100μl of multicells’ lysate (obtained from U87 cells at different concentration of 105cells/cc 
down to 10
4
cells/cc) containing GFAP at a known concentration (from 40nM). The incubation was 
conducted at room temperature for 1h and, after a preventive washing protocol similar to those 
conducted after incubation in standard conditions, the height of the NAMs was analyzed by AFM to 
validate the experimental session.  
 
2.4 Signal to noise ratio and roughness analyses  
of the SAMs and NAMs 
 
The three preliminary steps (grafting of ssDNA, hybridization of cDNA+STV, 
immobilization of GFAP Abs) needed to realize the nano-immuno arrays above described, along 
with the subsequent immobilization of GFAP in standard conditions and in the multicells’ lysate 
were confirmed by topographic analysis performed with AFM.  
The fabricated nanopatches were imaged after resetting the value of the perpendicular force 
load to the smallest possible, still detectable, value. Each imaging session was conducted using a 
cantilever characterized by a stiffness of 0.03 N/m (CSC 38, MikroMasch) in a 300μl solution of 
TE or TBS or PBS (as specified above), with the following parameters: pixel size: 256 x 256, and 
scan rate: 1Hz. For each step not only the relative height reached by the NAMs, but also their 
roughness with respect to the surrounding TOEG SAM were measured by scanning side by side the 
patches within the SAM at a minimum force (always lower than 0nN, and in any case as much close 
as possible to values of set point loss) and constant speed (1000nm/s).  
The imaging parameters were appropriately chosen to avoid any misleading compression of 
the tip over the scanned area, thus respecting characteristics acquired by the surface after each 
single step. All experiments were performed at least in triplicate, and the given values and errors 
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correspond to the mean values and standard deviation of height obtained from at least three 
independent patches. The evidence of a progressive NAMs’ height increase was meant to confirm 
their selectivity in recognizing step by step the appropriate ligand.  
 
2.5 Benchmark tests with ELISA 
 
Being ELISA the most standardized method for protein detection, it served as a benchmark 
to compare the sensitivity acquired with the above-described nano-immuno array and a diagnostic 
tool daily used in the clinical practice.   
Microtiter plates were coated with 200ng of GFAP anti-mouse IgG (Synaptic System) in 0.1 
M sodium carbonate (pH 9.6) overnight at 4°C and were blocked with 3% Bovine Serum Albumine 
(BSA) (Sigma) in Phosphate Buffered Saline containing 0.05% Tween 20 (PBST) for 12 hours. 
After three washes with PBST, plates were transferred at room temperature and incubated with 
100μl cells’ lysates and different concentrations of GFAP protein (Synaptic System) diluted in 
100μl blocking solution for 2h.  
Plates were washed three times with PBST and incubated for 1h with a 1:1000 dilution of 
biotinylated GFAP Abs. This was followed by three washes with PBST, and an incubation of 1h 
with the HorseRadish Peroxidase (HRP)-conjugated Streptavidin (Millipore), in a 1:5000 dilution in 
blocking buffer.  
Finally, plates were washed three times with PBST and developed with TMB reagent 
(Sigma) for 5 min before the reaction was stopped by the addition of 1M H2SO4. Absorbance at 
450nm was measured in a plate reader (Titertek Multiskan MCC/340). 
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3.1 Patterning of living cells 
 
The fabrication and functionalization of microwells was operationally straightforward: in 
fact it requires no special equipment but a clean room, and the latest step for PDMS curing and 
peeling can be carried out in a conventional laboratory on an inexpensive optically transparent 
polymeric support (see Fig 3.1).  
 
 
Fig 3.1: PDMS microwells 
 
The main advantage of the PDMS substrates is that they theoretically allow to pattern any 
cell within microwells of the desired diameters, in order to confirm this assumption we initially 
tested them trying to pattern prokaryotes with microfabricated wells of very small dimensions: 
10µm in diameter and 1µm in height (see Fig 3.2). 
 
Fig 3.2: 3-D imaging of PDMS-molding microwells fabricated at IOM INFM @ TASC, Trieste 
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3.1 a) Tests with Prokaryotes 
 
This set of experiments, carried out with E.Coli (see Fig 3.3), confirmed that those 
prokaryotes are able to adhere and survive with or without administration of growth medium, for at 
least 1h even within non-functionalized PDMS microwells (see Fig 3.4).   
 
Fig 3.3: Non-contact AFM micrograph in air of E.Coli deposited onto a mica surface 
 
Fig 3.4: Inverted optical microscope image showing adhesion, survival and replication of E.Coli  
even within non-functionalized microwells 
  
Although not operationally deemed for the prototyping of the device tested in this project, 
those high informative results open the way to further researches aimed at patterning living E.Coli. 
Noteworthy those bacteria are commonly utilized for several bioengineering purposes, therefore an 
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assessment of genetically modified strains of E.Coli within similar devices, appropriately created 
for their patterning and proteomic analysis, could be easily conducted in the near future. 
 
3.1 b) Tests with Eukaryotes 
 
Eukaryotic cells are typically much larger than those of prokaryotes: they have a variety of 
internal membranes and structures, called organelles, and a cytoskeleton composed of microtubules, 
microfilaments, and intermediate filaments, which play an important role in defining the cell's 
organization and shape. According to the final purposes of astrocytes’ analysis, PDMS microwells 
were finally fabricated with appropriate dimensions of 100µm in diameter x 100µm in height.  
Analyzed with an inverted optical microscope, a series of initial tests over non-functionalized 
PDMS surfaces rapidly showed that their tailored functionalization with adhesion substrates, such 
as polyornithine, is a mandatory step to successfully achieve adhesion and survival of eukaryotes, 
such as hyppocampal cells, within microwells (see Fig 3.5). 
 
 
Fig 3.5: Patterning of hyppocampal cells on non-functionalized (left)  
and functionalized (right) PDMS surfaces. 
 
The microcontact printing strategy exploited to functionalize the PDMS microwells yielded 
to a successful deposition of polyornithine only within the microwells: in fact the use of lucifer 
yellow to mark its presence nicely demonstrated their effective functionalization, as indicated by the 
fluorescent signal only in the well’s floor and walls (see Fig 3.6).  
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Fig 3.6: Functionalization of PDMS microwells with polyornithine stained in green  
thanks to lucifer yellow 
 
In conclusion, these series of tests demonstrated that the microfabrication and 
functionalization processes are easily performed, and that they allow for a feasible and effective 
patterning of living CNS cells within PDMS microwells of the appropriate dimensions.  
 
3.2 Optimizing the recognition of GFAP 
 
As a first test meant to rule out any unspecific alteration of the TOEG SAMs (TOEG3 as 
well as TOEG6) after incubation with biological samples, 100μl of cells’ lysate obtained firstly 
from prokaryotes (E.Coli) and lately from eukaryotes (HeLa cells) were deposited onto the SAMs, 
the incubation time lasted 1h at room temperature. Pre- and post-incubation imaging sessions were 
carried out throughout AFM-based roughness analysis in a solution of PBS 300μl with soft 
cantilevers (CSC 38, MikroMasch) and the following parameters: scan rate of 2000nm/s, pixel size 
256 x 256.  
These initial tests did not show any significant difference in terms of roughness of the SAMs 
as calculated before and after cell’s lysate deposition, confirming the suitability of TOEG SAMs for 
their promising functionalization oriented toward effective nano-immuno recognition of the proteins 
of interest (see Table 3.1).  
 
 
100 μm 
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Scan Size 
Roughness Analysis 
 PBS Cells’ Lysate (1h) 
 1μm 155.7pm 143.1pm 
TOEG3 5μm 139.7pm 132.8pm 
 10μm 135.7pm 143.0pm 
 1μm 145.2pm 132.0pm 
TOEG6 5μm 158.3pm 145.2pm 
 10μm 147.5pm 148.5pm 
Table 3.1: Physical properties (roughness) of TOEG surfaces are not altered 
after incubation with cell’s lysate 
 
3.2 a) Antibodies’ immobilization 
 
The fabrication of nanosized patches of biotin terminated alkanelthiol by AFM-based 
nanografting inside a matrix of SAM of alkanethiol-modified gold surfaces, rapidly yielded to a 
successful immobilization of biotinylated monoclonal GFAP Abs. On average the final NAMs’ 
height was 11 ± 1nm, as confirmed by topographic imaging conducted in TBS with the AFM (see 
Fig 3.7).  
 
 
Fig 3.7: Successful immobilization of GFAP Abs onto NAMs of biotin terminated alkanethiol 
46 
 
Taking into account that the height of the TOEG6 monolayer, well known in our laboratory 
from extensive sets of previous measurements, ranges from 1.9nm to 2.1nm, each progressive 
increase, step by step observed, in the NAMs’ relative height (Δh biotin+STV ≈ 6 nm and Δh GFAP 
Abs ≈ 3 nm) is compatible with crystallographic data (biotin+STV: 3nm x 6nm x 6nm; GFAP Abs 
4nm x 2.5nm x 3nm) sorted from the literature according to Protein Data Bank 
(www.wwpdb.org).Noteworthy, the initial height of the biotin-modified alkanethiol (C16) 
nanopatches was only ≈ 0.2nm, as calculated from the difference between the assumed TOEG6 
height of 2.2nm and the measured difference of 2.0nm between TOEG6 and the alkanethiol patch, 
and is certainly far too low for a standing-up alkanethiol monolayer. Nevertheless, since 
nanografting was performed in a water solution, and the used alkanethiol is not very soluble in 
water, what might have happened is that only few alkanethiol molecules were released in the 
nanografted area, probably adopting a laying-down conformation. Moreover, being the van der 
Waals radius of C ≈ 0.17nm, we should have expected to measure a 0.34nm absolute height after 
biotin terminated alkanethiol nanografting, so that a possible reason for this low initial height of the 
biotin-modified alkanethiol could probably be related to an excessive tip compression.  
Although this strategy confirmed to be very effective and straightforward its unsuitability 
for multiplexing assays fostered the subsequent trials meant to optimize the DDI protocols for 
antibody/protein arrays. The first experiments testing the DDI strategy for immobilization of 
biotinylated Abs were carried out with cF4 ssDNA (5’-ctt att tta ttg tta tac gcc c-3’) along with its 
cDNA already functionalized with a tyrosine binder-tag. Those tests led to progressive increase in 
the NAMs’ height till to the hybridization of ssDNA with the STV-cDNA complex. In fact the 
binding between the tyrosin binder tag of the cF4 cDNA conjugate, and one of the 6 tyrosin chains 
of STV was obtained in solution before incubation with the ssDNA patches. As a result after 
immobilization of ssDNA and formation of the dsDNA+STV the measured relative height with 
regard to the TOEG monolayer were 6.8 ± 1.2nm and 13 ± 2.7nm respectively. Taking into account 
that the height of the TOEG monolayer ranges from 1.9nm to 2.1nm, we obtained an absolute 
height of the ssDNA of ≈ 8.7nm.  The fully stretched length of a 24 nucleotides DNA, as the one 
used in this experiment, is expected to be ≈ 8.2nm + 1.2nm = 9.4nm, having taken into account the 
length of the C6 alkanethiol linker (1.2nm) attached to the ssDNA 3’ termination. Following the 
study performed by Mirmomtaz and colleagues on variable density DNA patches, which correlates 
DNA patch height to DNA surface density (Mirmomtaz et al, 2008), we can conclude that our 
nanopatches had a concentration of molecules in the upper end of 10
12
mol cm
-2
 range (probably. 7 - 
9), and is definitely below saturation (3 x 10
13 
mol cm
-2
). This condition corresponds to optimal 
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hybridization efficiency, and explains the correct formation of dsDNA-STV complexes (see Fig 
3.8). 
 
 
Fig 3.8: Successful hybridization of STV onto NAMs of cDNA with a tyrosin binder tag 
 
 Unfortunately none of the trials conducted with cF4 with the explained strategy yielded to a 
successful immobilization of biotinylated GFAP Abs: because of an uncontrollable lack of stability 
of those NAMs, the experiments were subsequently carried out with cF9 ssDNA (5’-ctt gat tgc cac 
ttt cca c-3’) and its cDNA already functionalized with a STV-tag.  
Nevertheless, those trials did not allow, initially, to obtain the hybridization between ssDNA 
and its conjugated-cDNA, instead a dramatic decrease in NAMs’ height was always observed (see 
Fig 3.9).  
To overcome this problem a similar strand of DNA, cF5 ssDNA (5’-ctt atc tta tga ccg gac c-
3’), along with its cDNA already functionalized with a STV-tag was tried (see fig 3.10).  
Even with this DNA strand the hybridization did not lead to an increase in NAMs’ height as 
expected; instead those experiments confirmed as in the previous set with cF9 a decrease below 
initial ssDNA values. To understand the reasons for those failures each single step of the DDI 
protocol, its multiple parameters and every buffer utilized were independently assessed multiple 
times. Lastly, while struggling against these problems, concerns have been raised on the integrity of 
both the cDNA strands (cF9 and cF5) conjugated with  STV. 
48 
 
 
Fig 3.9: Decrease in the NAM’s height following the tentative hybridization between cF9 ssDNA and its 
cDNA directly conjugated with STV 
 
 
Fig 3.10: Decrease in the NAM’s height following the tentative hybridization between cF5 ssDNA and its 
cDNA directly conjugated with STV 
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To test this hypothesis a Sodium Dodecyl Sulphate - PolyAcrylamide Gel Electrophoresis 
(SDS PAGE) assay, usually the first choice to assess protein purity due to its high reliability was 
conducted at the Structural Biology Lab @ Elettra.  
Surprisingly, this SDS PAGE revealed a remarkable degradation of the STV tag, whose 
molecular weight is expected to be ≈ 60kDa (see Fig 3.11).  
 
Fig 3.11: SDS PAGE of a DNA strand already functionalized with a STV-tag (right, note the absence of the 
expected STV stacking at 60kDa) versus control STV (left) 
 
This result supported the internal speculations raised about the responsibility of the cDNA-
STV construct, their possible degradation and consequent poor stability, for the failure of such set 
of experiments.  
At the same time comforted by this SDS PAGE assay, we ruled out any doubt concerning 
the protocol itself.  
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The DDI strategy was therefore applied again, without changing the already optimized 
parameters but using a completely brand new batch of cF5 (5’-ctt att tta ttg tta tac gcc c-3’) ssDNA 
and its freshly conjugated STV-cDNA (see Fig 3.12).  
 
 
Fig 3.12: Successful immobilization of GFAP Abs onto DDI NAMs (imaging in TE) 
 
 
Fig 3.13: Progressive increase in NAMs’ height in blocking buffer only (imaging in TE)   
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Those experiments yielded to a successful progressive increase in the relative NAM’s 
height, on average from 5nm (ssDNA), to 10nm (cDNA+STV) till to 13nm (cDNA plus GFAP 
Abs) with respect to TOEG6. 
Before proceeding to the experimental session dedicated to the recognition of GFAP, the 
behaviour of those NAMs was tested with biological samples in a multicells’ lysate obtained from a 
eukaryote cell line (U87 glial culture).  Accordingly the nano-immuno arrays were tested before and 
after functionalization with GFAP Abs by depositing on top of them 100μl of cells’ lysate each time 
for 1h at room temperature.  
Pre- and post-incubation imaging sessions were routinely carried out throughout AFM-based 
roughness analysis in a solution of PBS 300μl with soft cantilevers (CSC 38, MikroMasch) and the 
following parameters were applied: scan rate 2000nm/s, pixel size 256 x 256.  
This experiment confirmed that the roughness of both NAMs and SAMs did not change 
significantly before and after incubation with cell’s lysate, while the STV-tag of those NAMs still 
retain the specificity to appropriately immobilize biotinylated Abs (see Table 3.2).  
 
 
Table 3.2: Roughness Analysis with/without (w/wo) cell’s lysate 
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After a long and continuous optimization of the DDI protocols, a better understanding of this 
strategy was finally achieved, developing a promising expertise in such a bottom up nanofabrication 
and nanofunctionalization technique.    
Nevertheless, despite such encouraging results many aspects needed to be addressed: 1) the 
role of blocking buffers on the selectivity of the antigen antibody recognition, and 2) the ability of 
those NAMs to recognize the protein of interest in a cells’ lysate.  
  
3.2 b) GFAP in PBS 
 
To verify the efficacy of blocking buffers to reduce the background noise or to prevent 
unspecific staining in presence of the ligand, the subsequent imaging sessions were always 
conducted in PBS, which is much more tailored for imaging of biologically active biosensors.  
Noteworthy, when the experiment was repeated step by step, utilizing the abovementioned 
TBS buffer instead than TE (≈ 150mM), the progressive increases in relative height resulted slightly 
higher (see Figs 3.14 and 3.15). This result is conceivable since the two buffers have different ionic 
strengths: the higher is the ionic strength, the higher the screening of the electrostatic charge, the 
more the molecules adopt a compact conformation (i.e. lower height). 
 
Fig 3.14: Successful immobilization of GFAP Abs onto DDI NAMs (imaging in TBS) 
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Fig 3.15: progressive increase in NAMs’ height in blocking buffer (imaging in TBS)   
 
3.2 c) GFAP in multicells’ lysate 
 
The suitability of those nano-immuno arrays to selectively recognize the protein of interest 
not only in presence of recombinant GFAP alone but also in the cells’ proteome, which contains 
several different proteins potentially responsible for unspecific bindings over the NAMs or over 
the surrounding SAM, was finally tested by incubation of the SAM in a solution of 100μl of 
blocking buffer containing multicells’ lysate (obtained from U87 cells at different concentration 
of 10
5
cells/cc down to 10
4
cells/cc) and recombinant GFAP at a known concentration of 40nM. 
 Starting from a relatively small, known concentration of 40nM, we observed that the final 
NAMs height corresponded to 32 ± 2.8nm, almost similar to the 29.4 ± 2.2nm registered in a 
solution of 100μl of blocking buffer containing only recombinant GFAP at a known 
concentration of 40nM (see Figs 3.16 and 3.17). 
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Fig 3.16: progressive increase in NAMs’ height in blocking buffer  
plus multicells’ lysate (imaging in TBS) 
 
 
Fig 3.17: Final height of the nanopatches after incubation with recombinant GFAP in PBS and after 
incubation in the cells’ proteome at the same concentration of GFAP (40nM) 
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Indeed, the evidence of a progressive NAMs’ height increase confirmed the functionalized 
NAMs retain their selectivity in recognizing step by step the appropriate ligand. Moreover the 3-D 
images of the nano-immuno arrays, routinely obtained at the end of every step to check at a glance 
that the area surrounding each NAM was clean, suggested that the multicells’ lysate did not 
influence nor the antigen-antibody recognition nor the subsequent height analysis (see Fig 3.18). 
 
 
Fig 3.18: Successful  recognition and immobilization of GFAP in multicells’ lysate: both SAMs 
and NAMs are not affected by binding of unspecific proteins contained in the cells’ lysate 
 
Actually, the results herein presented confirm that on one hand, nanografting has unique 
capabilities for controlling density and conformation of patterned biomolecules at the nanometer 
scale; on the other, the inner characteristics of DDI, such as high efficiency of adsorption, site-
selectivity and reversibility, allow for selective immobilization of a specific protein of interest on 
the generated DNA patterns using semisynthetic protein-DNA conjugates. 
Once the proof of concept was obtained, a determination of the sensitivity of those nano-
immuno arrays remained to be realized: for this reason we focused toward increasing the 
experimental data to realize a titration curve and compare it with that of ELISA.      
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3.3 Challenging the sensitivity of ELISA 
 
Once optimized the antibody detection using a cells’ lysate, we also decided to show the 
possibility to quantitatively determine the concentration of GFAP in the sample. We decided to 
obtain the affinity curve for our nanobiosensor assay by measuring the variation of the height on the 
biosensor after the incubation with a solution containing a fixed concentration of the protein of 
interest in blocking buffer. We therefore monitored the height variation on the patches topped with 
the GFAP Abs ranging from 200pM to 100nM showing a sigmoidal behaviour as expected for the 
binding of an antigen to antibody (see Fig 3.19).  
 
Fig 3.19: Titration curve of the nano-immuno arrays’ sensitivity for GFAP.  In black the experimental values 
(from 200pM to 100nM) and in red the fit with the Hill equation. From the fit we obtained: hmin= 0.78 ± 
0.28nm, hmax = 5.07 ± 0.75nm, n = 1.43 ± 0.82 and KD = 6.6 ± 3.8nM 
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In order to quantitatively describe the recognition of GFAP via our nanobiosensor assay, we 
utilized a standard sigmoidal curve (Hill equation) with the following formula: 
 
 
 
where hmin is the minimum height variation expected, hmax is the height variation upon saturation of 
our biosensor, KD is the microscopic dissociation constant and n is the Hill coefficient that quantify 
the cooperativity of the binding.  
 From the fit, we obtained a dissociation constant in the nanomolar range, with a dissociation 
constant equal to KD = 6.6 ± 3.8nM, and a slightly cooperative effect (n >1). However the large 
error in the Hill coefficient could mask the fact that the system has also a negative cooperative 
effect: meaning that once an antigene binds to an antibody, then the affinity of the antibody for 
another antigene decreases. In fact on our biosensor we expect that the steric hindrance between 
proximal Abs on the patches could contribute decreasing the cooperativity. 
In order to study the binding affinity curve of our nanobiosensor assay with a standard 
technique, we produced an ELISA assay for GFAP using the same Abs (see Fig 3.20) and we 
analogously fit the values of absorbance with Hill equation.  
The parameters obtained are n = 1.51 ± 0.26 that is compatible with a cooperative effect of 
the recognition event, and a dissociation constant equal to KD = 8.30 ± 1.04nM that is perfectly in 
agreement with the value found for the nanosensor assay.  
On a global perspective the results herein obtained are very promising: those data in 
particular allow envisioning the possibility for our nanodevice to be a valid alternative to ELISA 
assays.  
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Fig 3.20: Sensibility of ELISA in GFAP recognition from 200pM to 100nM. In black the 
experimental values and in red the fit with the Hill equation. From the fit we obtained: Absmin= 0.00 ± 0.01, 
Absmax = 1.55 ± 0.10, n = 1.51 ± 0.26 and KD = 8.30 ± 1.04nM 
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4.1 Clinical Considerations 
 
Clinicians are nowadays at a crossroad where therapeutic choices are being made not only 
considering conventional histological diagnosis but also the latest insights from molecular biology 
(Odreman et al, 2005). A significant body of evidence demonstrates that even genetically identical 
cells can exhibit significant functional heterogeneity, accordingly molecular cancer diagnostics is 
rapidly moving beyond genomics to proteomics, with the aim to identify those post-translational 
modifications expressed under pathologic conditions (Krutzik et al, 2004). The proteome and 
secretome by definition are dynamics and change both in physiologic and pathologic conditions; the 
ultimate goal of determining them is to characterize the flow of information within the cells, 
through the intercellular protein circuitry that regulates the extracellular microenvironment. Indeed, 
the study of proteomics and molecular biomarkers already allows to identify direct or indirect 
predictive factors, and soon it will hopefully determine which affected pathway could become a 
selective therapeutic target. Accordingly, nanotechnology-based approaches are being extensively 
explored to discover, identify and quantify clinically useful molecular signatures for early detection, 
diagnosis and prognosis of several tumors.  
 
4.1 a) Genetic and Proteomic Features of Gliomas 
 
One of the insidious biological features of gliomas is their potential to extensively invade 
normal brain tissue, yet molecular mechanisms that dictate this locally invasive behavior remain 
poorly understood (Ohgaki et al, 2005; Maruo et al, 2012).  
To date many chromosomal and genetic aberrations involved in the genesis of high grade 
gliomas have been outlined, showing interesting relationships between survival, pathobiology, and 
molecular signature responsible for the formation of primary (de novo) and secondary (progressive) 
Glioblastomas (Mendoza-Maldonado et al, 2011) Although histologically indistinguishable, these 
WHO Grade IV tumors occur in different age groups and present distinct genetic alterations 
affecting similar molecular pathways (Brandes et al, 2010).  
For example the inactivation of p53, a proapoptotic protein, may occur due to direct 
mutation in progressive Glioblastomas, or amplification of E3 ubiquitin-protein ligase Mdm2 
(MDM2), a negative regulator of the p53 tumor suppressor gene, in de novo ones. Similarly, 
activation of the phosphonositide 3-kinase (PI3K) pathway, a family of enzymes involved in 
cellular functions such as cell growth, proliferation, differentiation, motility, survival and 
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intracellular trafficking, is induced by several cooperative mechanisms including: mutation of the 
tumor suppressor gene phosphatase and tensin homolog (PTEN), as well as epidermal growth factor 
receptor (EGFR) amplification and mutation (Furnari et al, 2007). 
Immunohistochemical markers are therefore important and rapidly evolving tools in the 
classification and neuropathological diagnosis of malignant gliomas. Currently, among the markers 
for classification of gliomas, the most clinically useful and specific are GFAP and oligodendrocyte 
transcription factor 2 (OLIG2). In particular, GFAP is universally expressed in astrocytic and 
ependymal tumors and only rarely in oligodendroglial lineage tumors, thus serving as an effective 
tool for unequivocal identification of gliomas and their distinction from non-CNS tumors, while 
aiding the pathologist in the distinction of different glioma classes (Furnari et al, 2007). 
The above described scenario gives an idea of the cellular and molecular complexity of the 
gliomas’ microenvironment suggesting the importance to understand intracellular and intercellular 
signaling. Recently, an expanded collection of novel markers has emerged from numerous avenues 
of research and holds potential to be deployed to improve classification and inform the potential 
clinical course of glioma patients. Among them, newly discovered stem and progenitor cell markers 
are of particular interest because once clinically validated, they might aid in the differential 
diagnosis of these tumors as well as in the monitoring of their responses to therapy (see Fig 4.1).  
 
 
Fig 4.1: Role of stem cells in tumor recurrencies.  
Drawing adapted from: Rahman M et al, Future Oncol 2012 
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Intensive research efforts are recently attempting to uncover agents that may target 
subpopulations of these cells with high tumorigenic potential and increased resistance to current 
therapies. Along these lines, the cell surface marker, CD133, and other markers of stem cells, such 
as Nestin, have been shown to negatively correlate with outcome parameters (Mao et al, 2007). To 
this regard Singh and colleagues showed that CD133+ brain tumor cells can self-renew and undergo 
lineage-specific differentiation (Singh et al, 2003). Certainly, these newly discovered markers 
suggest that pathologists will soon have at their disposal highly useful tools for improving the 
clinical diagnosis and classification of gliomas. 
 
4.2 Methodological constraints and opportunities 
 
Different ways to immobilize DNA molecules or specific proteins of interest have been 
subject of intensive research over the last years: the strongest efforts being put into the optimization 
of nano- to femtomolar detection of bioanalytes onto functionalized arrays surfaces. Understanding 
the structure and function of each protein and the complexities of protein–protein interactions will 
be critical for shaping the most effective proteomic instruments in the future. In general, among the 
complex aspects characterizing the development of biosensors the most intriguing one is certainly 
the individual conditioning of the different elements that must be assembled: proteins, DNA and 
antibodies must in fact maintain their functional conformation throughout the assay procedure, 
despite relevant differences in electrical charge, hydrophobicity, post-translational modification and 
folding (Ling et al, 2007). To date a number of techniques have emerged as effective tools for the 
discovery of key biomarkers, nevertheless a combination of multiple techniques is mandatory to 
attain the goal of measuring multiple parameters in a single living cell, and only the hybridization of 
proteomic methods with protocols and devices for cells patterning is finally yielding to the 
development of arrays for few cells proteomics. 
 
4.2 a) DDI-based proteomic assays 
 
Our approach utilized DNA self-assembly as a means to array antibodies specific for tumor 
biomarkers with well-defined size and spacing features. Such very general sensitive, reproducible, 
label free, miniaturized diagnostic platform seems particularly suitable for a parallel detection of 5 
to 8 circulating tumor biomarkers, including cell-surface and intracellular biomarkers obtained in 
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vitro from tumor’s lysate, or cytokines and other cell-signaling proteins detected in vivo from their 
secretome,  in a quantitative manner and at a low cost (see Fig 4.2).  
Due to the miniaturization and to its array format, our device can be easily made to face a 
microfabricated array of microwells with potentiality for single cells secretome analysis. 
 
 
 
Fig 4.2: Intended functionalization of adjacent nano-immuno arrays for multiplexing analysis 
 
Based on previous results obtained in our laboratory, we optimized the fabrication of DNA 
nano-immuno arrays as a first step towards the immobilization of Abs specific for certain proteins 
of interest, through an approach consisting in DDI of DNA-conjugated Abs. The device read-out 
consisted in AFM differential topographic height detection: upon binding of the target, the 
nanopatch height is expected to change, as a function of the number of biomolecules captured by 
the Abs on the nanospot. The feasibility of such kind of approach to detect, as a proof of principle, 
anti-streptavidin (STV) and anti-GoX (glucose oxidase) Abs was already experimentally 
demonstrated few years ago (Fruk et al, 2007; Bano et al, 2009), but only recently, we achieved the 
necessary expertise to successfully compare these nanodevices against standard ELISA assays on 
GFAP. With respect to ELISA, where the protein capture molecules are physisorbed on the surface 
and therefore randomly oriented, our assay shows unique capabilities for controlling and optimize 
density, binder directionality and to preserve its structural native conformation at the nanometer 
scale, with a strong impact on device sensitivity and reproducibility.  
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The binding affinity (titration) curves obtained to date from our nanobiosensor assay by 
measuring the variation of the height at the Abs-containing nanospot after the incubation with a 
solution containing a fixed concentration of the protein of interest in blocking buffer (following 
exactly the same protocols used for ELISA), confirms that the sensitivity of our nanosensors is at 
least that of ELISA, with the advantage of the scalability of the device.  
Reducing the diffusion time of the solute, by exposing only the active area of the device to 
the solution (going to microliter to nanoliter), we could expect to easily increase the sensitivity of at 
least one order of magnitude. At this point, the optimization of the surface density of the DNA 
capture molecules on the device will be crucial. Experimental evidence that the hybridization limit 
of such nanodevices could be primarily and intrinsically controlled by molecular crowding are in 
fact arising.  
  
4.2 b) Comparison with ELISA-based proteomic assays 
 
The current standard for immunoassays and emerging molecular diagnostics is to analyze 
one analyte only: specifically, one aliquot of a patient sample (serum, plasma or tissue specimens) 
is processed and tested for one analyte at a time. Pressure for more accurate tests supported the 
extensive research to achieve state of the art performance of relatively simple assays.   
As a reflection, ELISA is one of the most important bio-chemical techniques used mainly to 
detect the presence of Abs or antigens in a sample based on antibody-antigen immunoreactions (Jia 
et al, 2009).  
Due to its simplicity, low cost, easy reading, acceptability and safety (Engvall and Perlman, 
1971; Lequin et al 2005) ELISA is widely used for detection of cancer protein markers, pathogen, 
and other proteins relative to various diseases with detection limit from 0.1 ng to 1 μg mL-1 (Engvall 
and Perlman, 1971; Koppelman et al, 2004).  
However, the knowledge of specific tumor protein markers is still limited, especially for 
certain tumors such as high grade gliomas; on the other hand the level of those markers is very low 
at the early stage of several cancers and therefore beyond the detection limit of the state-of-the art 
diagnostic techniques.  
Moreover, the demand for parallel, multiplex analysis of protein biomarkers from ever 
smaller biospecimens, such as those obtained with stereotaxis biopsies or after cell sorting of more 
abundant neoplastic specimens meant to identify tumor stem cells (i.e. CD133 glial cells), is an 
increasing trend for both fundamental biology and clinical diagnostics.  
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The need for increasing the current detection sensitivity, while searching for key proteins in 
smaller sample volumes, is therefore among the main triggering factors that led to the development 
of methods for single cells analyses. Attempts included miniaturization and mimicking of 
conventional proteomic protocols as well as exploration of novel ideas and techniques that enable 
new types of experiments, expanding the scientific field of “cells on a chip” in “single cells on a 
chip” (Lindstrom et al, 2011). 
 
4.2 c) Trends in single cells DNA barcode analysis 
 
The demand for parallel, multiplex analysis of protein biomarkers from even smaller 
biospecimens is an increasing trend for both fundamental biology and clinical diagnostics (Heath et 
al, 2008).  
To date, the most highly multiplex protein assays rely on spatially encoded antibody 
microarrays, this approach capitalizes on the chemical robustness of DNA oligomer strands and on 
the reliable assembly of DNA labeled structures via complementary hybridization (Shin et al, 
2010).  
Recently the miniaturization of conventional techniques let to the development of DNA 
barcode-type arrays at 10-times higher density than standard spotted microarrays, potentially 
enabling for high-throughput and low-cost measurements.  
Generally speaking, the immunoassay region of the chip should ideally be a microscopic 
barcode customized for the detection of many proteins and/or for the quantization of a single or few 
proteins over a broad concentration range.  
Accordingly, using the DNA-encoded antibody library technique, Fan and colleague 
developed and optimized an antibody array applied towards the measurement of a highly multiplex 
panel of proteins from small whole blood specimens (range of μl obtained through finger prick). 
The versatility of their barcode immunoassay is demonstrated by the ability to stratify cancer 
patients via multiple measurements of a dozen blood protein biomarkers for each patient (Fan et al, 
2008).  
This technique was further applied by coupling it with the immobilization of living cells, 
with an outlook for multiplex assay of citoplasmic proteins. Shin and colleagues for example, were 
able to detect simultaneously not only enzymes, such as phospho-extracellular signal regulated 
kinase (ERK), but also receptors, such as EGFR, both key nodes of the PI3K signaling pathway of 
glioblastomas, at concentrations of 10 to 1 ng/ml (Shin et al, 2010; Shi et al, 2012).   
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The coupling of DNA barcode analysis with immobilization and characterization of few to 
single cells represented a remarkable boost for cancer proteomics, in fact among the advantages of 
single cells analysis the main one is certainly the possibility to foster qualitative protein 
measurements, but in a quantitative fashion (Shi et al, 2012). One example relates to the 
interrogation of cross talk between signaling pathways within a cellular population as a paradigm to 
understand the overall tumor architecture: in their experiments Wang and colleagues assessed how 
cell-cell contacts and soluble factor signaling influence interaction among a glioma cell line (Wang 
et al, 2012).  
In particular they interrogated the activity associated with PI3K signaling in a model of 
glioma cancer (U87 cells line) as a function of cell-cell separation: their results indicated that only a 
subpopulation of cells presented a constitutive activation of EGFR while the majority did not. This 
finding not only confirms that such approach allows for a thorough quantitative in vitro analysis of 
the proteome of few living cells, but also for a simulation of their hypothetical behavior in vivo: in 
line with the hypothesis that the expression of EGFR in a subpopulation of cells represents a trigger 
for parenchymal invasion, its expression if the majority of the entirety of the tumor would not 
enhance tumorigenicity instead would create a self-inhibiting state.  
Hopefully, all these methodologies will soon increase the understanding of cellular 
pathways involved in high grade gliomas, so that tremendous advances might be expected within 
few years from now. With specific regard to the forthcoming steps of our research those advances 
could come on one hand from the exploitation of the potentialities for multiplexing analysis, 
demonstrated by our nanobiosensors, with concomitant detection of key biomarkers such as p53, 
nestin, EGF-R, OLIG2 or PTEN; on the other hand, aiming to increase the statistical value of the 
assays and therefore its clinical meaning, from the incubation of a relevant number of cells 
(hopefully ≈ 100, one for each microwell) obtained from homogeneous cell populations (perhaps 
sorted according to their positivity for CD 133).  
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Chapter 5:  
 
Conclusions and Outlook 
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5.1 Optimization of protocols for protein recognition 
 
 
The future of healthcare relies heavily on diagnostics: ideally, very early detection of unique 
molecular or protein patterns would allow for tailored treatments and management of many 
degenerative and neoplastic diseases (Stegh et al, 2013).  
There are two main challenges in the development of new analytical methods for detection 
of proteins of interest: the first one is the technological, the second purely qualitative:  
- The first technical challenge lies in reducing the quantities of biological specimens 
required for diagnostic assays, while scaling down the minimum amount of DNA or 
proteins that can be directly detected.    
- The second consists in increasing the overall knowledge in the field of protein 
characterization and its clinical usefulness by identifying specific pathologic biomarkers 
and clarifying the correlation between over-expression or under-expression of certain 
proteins and the subsequent clinical course.  
Indeed, the choice to optimize the DDI strategy, over the one consisting in the fabrication of 
nanosized patches of biotin terminated alkanethiol, was supported by the quest for multiplexing 
assays meant to overcome the current limits of single analyte assays. To this regard, the 
combination of nanografting with DDI meant for an easy, highly selective and precise arrangement 
of biomolecules, was already tested in a complex biological mixture represented by human serum 
(Bano et al, 2009); furthermore we have herein proved the ability of antibodies immobilized on the 
top of our nano-immuno arrays to preserve their specificity in the presence of a multicells’ lysate.  
Noteworthy, this strategy for realizing nano-immuno arrays seems particularly advantageous 
in terms of multiplexing analysis since the limiting factor for the number of protein tested is only 
the number of different DNA strands and antibody binding protein used. This technical feature 
could easily open the doors to future clinical applications of the diagnostic approach herein 
described. Especially because the accuracy achieved so far is a promising starting point to reach and 
eventually outreach the detection limits of ELISA protocols, while yielding to sensitivity 
maximization in term of sample quantities that are hardly accessible with conventional proteomic 
techniques.  
Moreover, the inherent capacity of nucleic acids to self-assemble, exploited here, would also 
permit novel approaches based on the spontaneous formation of water-soluble, programmable 
nanoassemblies with defined shape, size and functionalities, as for DNA origami (Rothemund et al, 
2006).  
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By introducing into our system a sandwich assay in which a second conjugated antibody, 
recognizing an independent epitope of the same protein, is combined via double-strand DNA 
interaction to a DNA-origami molecule modified with a fluorophore, we could combine the AFM 
topographic read-out to a fluorescence read-out. This approach could allow for fast screening and, 
perhaps for a further increase in the sensitivity of the system.  
Also, fluorescence can be gauged in order to equalize the dynamic range of the fluorescence 
signals corresponding to biomarkers having different dynamic range of expression. Fluorescence-
positive spots could then be analyzed by means of AFM topography read-out to check for eventual 
unspecific binding.  
The main drawback of our technique could be seen then in the time needed for the process of 
nanografting itself. Nanografting is in fact a serial process that requires few hours to produce an 
ideal mesh of, for instance, 5x5 spots of 1μm2, meaning 5 different DNA to load 5 different 
antibodies, each one repeated 5 times for statistical purposes.  
However, the DNA matrix produced by nanografting can be easily reproduced in multiple 
copies, by means of stamping techniques as SupraMolecular NanoStamping (Akbulut et al, 2007), 
with the possibility of producing from one master some tens of copies of (negative) DNA matrixes.  
Finally, in our system the technical ability of conjugate antibodies with DNA strand plays a 
major role, while the assay sensitivity is ultimately limited by the affinity of the chosen protein 
binder, i.e. the specific antibody-biomarker affinity. By choosing recombinant, single domain camel 
antibodies (in VHH format), having a mass of 15kDa (Aliprandi et al, 2010), which is 10-times 
smaller than a conventional IgG, more easy to functionalize or conjugate, we could prepare active 
surfaces with a significantly higher density, and we could identify Abs with optimal binding 
capacity for the in vivo receptor conformations, with the optimization of specific features (KD and 
stability). 
 
5.2 Toward Quantitative Neuroscience 
 
The next generation of nanotechology-based devises hold the promise for improved 
multiplexed sensing and therefore for a better diagnostic accuracy meant to eventually improve the 
outcome of oncological patients. The results herein described represent an initial step to test the 
sensitivity and, in line with the expectation of a forthcoming patient-tailored medicine, the 
specificity of nano-immuno arrays designed for the detection of pivotal biomarkers, such as GFAP 
involved in the pathogenesis of gliomas. To this regard the characterization of this DDI strategy will 
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soon allow for the concomitant detection of several proteins of interest, making this technique a 
valid alternative for the current benchmark of ELISA-based proteomic.  
Assaying a large panel of different proteins would not be possible without a high density 
antibody arrays, not just because they should be spatially constrained but also because of the high 
sensitivity required, therefore a consistent DNA loading across the nanoarray represents a 
meaningful strategy. The approach described of label-free nano-immuno detection, due to the 
promising results obtained in a multicells’ lysate, confirms its suitability to effectively work in a 
complex environment without being influenced by unspecific bindings with the many elements 
included in a cell’s proteome.  
The biosensor configuration and the possibility to pattern living cells within functionalized 
microwells allows to easily enhance common proteomic strategies, with a successful clinical 
downstream. To this regard an appropriate design of the DNA nanospot in terms of probe density, 
length, etc, to maximize the hybridization efficiency with the DNA-protein conjugates, could be 
made with the aid of molecular simulations. Although further studies are warranted to better 
characterize the multiplexing strategy, this step seems easily reachable in the next future; a further 
clinical challenge will then be to expand this platform toward the analysis of surgical specimens, 
eventually including the comparison with conventional clinical and pathological data.  
 
 
 
 
 
 
 
 
 
 
 
71 
 
Abbreviation List 
 
 
2DGE:   Two-dimensional gel electrophoresis 
 
Abs:   Antibodies  
AFM:    Atomic Force Microscopy  
 
cDNA:   Complementary DNA strand  
CNS:    Central Nervous System  
 
DDI:    DNA-Directed-Immobilization  
DPN:   Dip Pen Nanolithography 
 
EDTA:  Ethylene-diamine-tetraacetic acid 
EGFR:   Epidermal Growth Factor Receptor  
ELISA:   Enzyme-linked immunosorbent assay  
 
GFAP:   Glial Fibrillary Acidic Protein  
 
HRP:    HorseRadish Peroxidase  
 
IF:    Intermediate Filaments  
 
MALDI-TOF:  Matrix-assisted laser desorption ionization time of flight mass spectrometry  
MDM2:   E3 ubiquitin-protein ligase Mdm2  
MGMT:   O(6)-methylguanine-DNA methyltransferase  
 
NAM:    Nano Assembled Monolayer  
 
OLIG2:   Oligodendrocyte Transcription Factor 2 
 
PBS:    Phosphate Buffered Saline  
PBST:   PBS + Tween 20  
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PDMS:   Poly-dimethylsiloxane  
PI3K:    Phosphonositide 3-kinase  
PTEN:   Phosphatase and Tensin Homolog  
PVDF:   Polyvinylidene difluoride  
 
SAM:    Self Assembled Monolayer  
ssDNA:   Single Strand DNA  
STV:    Streptavidine  
 
TBS:    Tris Buffered Saline  
TBST:   TBS + Tween 20  
TE:   Tris-EDTA 
TMZ:    Temozolomide  
TOEG:   Alkanethiol-modified Gold  
Tris:   Tris(hydroxymethyl)aminomethane  
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